Document:

Exhibit 10.1

 

	Investor Name:	 
	Total Purchase Price:	USD$
	Combined Per Share-Warrant Price:	USD$3.50
	Number of Purchased Shares:	 
	Number of Warrants:	 

 

SUBSCRIPTION AGREEMENT

 

Glory Star New Media Group Holdings Limited

22F, Block B, Xinhua Technology Building

No. 8 Tuofangying South Road,

Jiuxianqiao, Chaoyang District, Beijing, China

 

Ladies and Gentlemen:

 

The undersigned (the “Investor”)
hereby confirms its agreement with Glory Star New Media Group Holdings Limited, a Cayman Islands exempted company (the “Company”),
as follows:

 

1. This
Subscription Agreement, including the Terms and Conditions for the Purchase of Ordinary shares and Warrants, attached hereto as Annex
I which is incorporated herein by this reference as if fully set forth herein (the “Terms and Conditions” and, together
with this Subscription Agreement, this “Agreement”) is made as of the date set forth below between the Company and the Investor.
Pursuant to this Subscription Agreement, the Company is agreeing to sell and the Investor is agreeing to purchase, ordinary shares of
the Company, par value of $0.0001 (the “Ordinary Shares”), and warrants, with each whole warrant exercisable to purchase one
Ordinary Share at an exercise price of USD$4.40 per share (the “Warrant(s)”). Warrants cannot be exercised for fractional
amount. The Investor agrees that all of its representations and warranties set forth herein, and the Terms and Conditions, are true, complete
and accurate as of the date hereof and the Closing Date.

 

2. The
Company has authorized the sale and issuance to the Investor of the number of Purchased Shares (the “Purchased Shares”) of
Ordinary Shares and Number of Warrants (“Purchased Warrants”) at the Combined Per Share-Warrant Price for an aggregate purchase
price of the Total Purchase Price. The Investor will pay the Total Purchase Price by cash.

 

3. The
offering and sale of the Ordinary Shares and Warrants and Ordinary Shares underlying the Warrants (the “Offering”) is being
made pursuant to (a) an effective Registration Statement on Form F-3, File No. 333-248554 (the “Registration Statement”) filed
by the Company with the Securities and Exchange Commission (the “Commission”), including the Prospectus contained therein
(the “Base Prospectus”), (b) if applicable, certain “free writing prospectuses” (as that term is defined in Rule
405 under the Securities Act of 1933, as amended (the “Act”)), that have been or will be filed, if required, with the Commission
and delivered to the Investor on or prior to the date hereof (the “Issuer Free Writing Prospectus”), containing only certain
supplemental information regarding the Ordinary Shares, the terms of the Offering and the Company, and (c) a Prospectus Supplement (the
“Prospectus Supplement” and, together with the Base Prospectus, the “Prospectus”) containing certain supplemental
information regarding the Ordinary Shares and terms of the Offering and the Company that has been or will be filed with the Commission
and has been delivered to the Investor prior to the Closing.

 

     1

     

    

 

4. (a) The Company and the Investor
agree that the Investor will purchase from the Company in tranches with each tranche payment at least USD$1,000,000 (herein referred as
“each tranche payment”) with an aggregated amount of all tranches which sum up to USD$10,000,000 and the Company will issue
and sell to the Investor the Purchased Shares and Purchased Warrants in accordance with each tranche payment within seven (7) business
days after the Investor sends the payment funds and bank payment receipt of each tranche to the Company. The Investor must complete the
purchase of the USD$10,000,00 in Purchased Shares and Purchased Warrants by September 30, 2021.

 

(b) Prior
to making a tranche purchase, Investor shall give written notice in the form attached hereto as Exhibit A of its intent to purchase additional
Ordinary Shares and Warrants to the Company at least five business days prior to the purchase.

 

5. The
manner of settlement of the shares of Ordinary Shares and Warrants purchased by the Investor shall be as follows:

 

(i) Delivery
of representation of stock ownership using Direct Registration System (“DRS”) representing the Purchased Shares purchased
by the Investor, .

 

(ii) Delivery
of a Warrant certificate representing the Purchased Warrants purchased by the Investor at the Investor’s address by the Company

 

NO LATER THAN 10:00 A.M. (EASTERN
TIME) ON THE THIRD BUSINESS DAY IMMEDIATELY AFTER THE DATE OF EXECUTION OF THIS AGREEMENT BY THE INVESTOR AND THE COMPANY, THE INVESTOR
SHALL:

 

(iii) Deliver
to the Company, this duly completed and executed Agreement and the first tranche payment.

 

6. The
Investor represents that it has received (or otherwise had made available to it by the filing by the Company of an electronic version
thereof with the Commission) the Base Prospectus, declared effective by the Commission on September 14, 2020, which is a part of the Company’s
Registration Statement and the documents incorporated by reference therein, any Issuer Free Writing Prospectus and the Prospectus Supplement
(collectively, the “Disclosure Package”), prior to or in connection with the receipt of this Agreement. The Investor acknowledges
that, prior to the delivery of this Agreement to the Company, the Investor may receive certain additional information regarding the Offering
and the Company (the “Offering Information”). Such information may be provided to the Investor by any means permitted under
the Act, including the Prospectus Supplement, a free writing prospectus and oral communications.

 

7. No
offer by the Investor to buy Ordinary Shares and Warrants will be accepted and no part of the purchase price will be delivered to the
Company until the Investor has received or has public access to the Disclosure Package and the Offering Information and the Company has
accepted such offer by countersigning a copy of this Agreement, and any such offer may be withdrawn or revoked, without obligation or
commitment of any kind, at any time prior to the Company sending (orally, in writing or by electronic mail) notice of its acceptance of
such offer. An indication of interest will involve no obligation or commitment of any kind until the Investor has been delivered the Disclosure
Package and Offering Information and this Agreement is accepted and countersigned by or on behalf of the Company.

 

     2

     

    

 

8. Representations
and Warranties of the Company. The Company hereby makes the following representations and warranties to the Investor:

 

(a) Subsidiaries.
The Company’s subsidiaries consist of (i) Glory Star New Media Group HK Limited, a limited company incorporated on December 18,
2018, under the Companies Ordinance of Hong Kong; (ii) Glory Star New Media (Beijing) Technology Co., Ltd., a wholly foreign-owned enterprise
established by Glory Star HK on March 13, 2019; and (iii) Xing Cui Can International Media (Beijing) Co., Ltd., a limited liability company
incorporated under laws of PRC on September 7, 2016, and (iv) Horgos Glory Star Media Co., Ltd., a limited liability company incorporated
under laws of PRC on November 1, 2016.

 

(b) Organization
and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to
own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in
violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational
or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected
to result in: (i) a material adverse effect on the legality, validity or enforceability of the Agreement, (ii) a material adverse effect
on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken
as a whole, or (iii) a material adverse effect on the Company’s ability to perform in any material respect on a timely basis its
obligations under the Agreement (any of (i), (ii) or (iii), a “Material Adverse Effect”)) and no Proceeding has been instituted
in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

 

(c) Authorization;
Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by the Agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Agreement by the
Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action
on the part of the Company and no further action is required by the Company and the Board of Directors in connection herewith. The Agreement
has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof,
will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i)
as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.

 

(d) No
Conflicts. The execution, delivery and performance by the Company of the Agreement to which it is a party, the issuance and sale of
the Ordinary Shares and the consummation by it of the transactions contemplated hereby and thereby do not and will not (i) conflict with
or violate any provision of the Company’s or any Subsidiary’s certificate or articles of incorporation, bylaws or other organizational
or charter documents, (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become
a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to
others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement,
credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company
or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental
authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any
property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could
not have or reasonably be expected to result in a Material Adverse Effect.

 

     3

     

    

 

(e) Filings,
Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to,
or make any filing or registration with, any court or other federal, state, local or other governmental authority in connection with the
execution, delivery and performance by the Company of the Agreement, other than: (i) the filings required pursuant to Section 9.4 of this
Agreement, and (ii) the notice and/or application(s) to the Nasdaq Stock Market (“Trading Market”) for the issuance and sale
of the Ordinary Shares and the listing of such Ordinary Shares for trading thereon in the time and manner required thereby (collectively,
the “Required Approvals”). There is no market for the Warrants and the Company does not plan on applying to list the Warrants
on any trading system.

 

(f) Issuance
of the Investor Ordinary Shares. The Ordinary Shares to be issued to the Investor (“Investor Shares”) are duly authorized
and, when issued and paid for in accordance with the Agreement, will be duly and validly issued, fully paid and nonassessable, free and
clear of all liens imposed by the Company other than restrictions on transfer provided for in the Agreement, if any. The Company has prepared
and filed the Registration Statement in conformity with the requirements of the Securities Act, which became effective on September 14,
2020, including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The
Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration
Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose
have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and
regulations of the Commission, shall file the Prospectus with the Commission pursuant to Rule 424(b). At the time the Registration Statement
and any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any
amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will
not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make
the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at time the Prospectus or any amendment
or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the
Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in light of the circumstances under which they were made, not misleading.

 

(g) Capital
Stock. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in
the transactions contemplated by the Agreement. The issuance and sale of the Investor Shares will not obligate the Company to issue Ordinary
Shares or other securities to any Person (other than the Investor) and will not result in a right of any holder of Company securities
to adjust the exercise, conversion, exchange or reset price under any of such securities. The Company does not have any stock appreciation
rights or “phantom stock” plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock
of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and
state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe
for or purchase securities. No further approval or authorization of the Board of Directors or others is required for the issuance and
sale of the Investor Shares. There are no stockholders’ agreements, voting agreements or other similar agreements with respect to
the Company’s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s
stockholders.

 

     4

     

    

 

(h) SEC
Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required to be
filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two
years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing
materials, including the exhibits thereto and documents incorporated by reference therein being collectively referred to herein as the
“SEC Reports”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports
prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the
requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue
statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject to
Rule 144(i) under the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material respects
with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time
of filing. Such financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (“GAAP”) applied on a consistent basis during the periods involved, and fairly present in all material respects
the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations
and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.

 

(i) Material
Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included within
the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof, (i) there has been no event,
occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has
not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course
of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements
pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the
Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or
made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to
any officer, director or Affiliate, except as disclosed in the SEC Reports. The Company does not have pending before the Commission any
request for confidential treatment of information. No event, liability, fact, circumstance, occurrence or development has occurred or
exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects,
properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities
laws at the time this representation is made or deemed made that has not been publicly disclosed at least one Trading Day prior to the
date that this representation is made.

 

(j) Litigation.
Except as disclosed in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or,
to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before
or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an “Action”) which (i) adversely affects or challenges the legality, validity or enforceability of any of the
Agreement or the Shares or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse
Effect. Neither the Company nor any Subsidiary any director or officer thereof (in his or her capacity as such), is or has been the subject
of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary
duty except as disclosed in an SEC Report. There has not been, and to the knowledge of the Company, there is not pending or contemplated,
any investigation by the Commission involving the Company or any current or former director or officer of the Company (in his or her capacity
as such). The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed
by the Company or any Subsidiary under the Exchange Act or the Securities Act.

 

     5

     

    

 

(k) Risk
Factors. An investment in the Company is subject to a number of risk and an Investor may lose all of his or her money. The material
risks that the Company may be subject to is set forth in the “Risk Factor’s section of the Registration Statement, the Prospectus
and the documents incorporated therein.

 

9. Other
Agreements of the Parties.

 

9.1 Shares
Sold Pursuant to a Registration Statement. The Ordinary Shares and Warrants to be sold to the Investor and the Ordinary Shares underlying
the Warrants (the “Securities”) when exercised will be made pursuant to an effective registration statement and the Ordinary
Shares and Ordinary Shares underlying the Warrants will be free of all legends. If at any time following the date hereof the Registration
Statement is not effective or is not otherwise available for the sale of the Investor Shares, the Company shall immediately notify the
holders of the Investor Shares in writing that such Registration Statement is not then effective and thereafter shall promptly notify
such holders when the Registration Statement is effective again and available for the resale of the Ordinary Shares underlying the Warrants
(it being understood and agreed that the foregoing shall not limit the ability of the Company to issue, or the Investor to sell, any of
the Investor Shares in compliance with applicable federal and state securities laws).

 

9.2 Furnishing
of Information. The Company covenants to maintain the registration of the Ordinary Shares under Section 12(b) or 12(g) of the Exchange
Act and to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be
filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements
of the Exchange Act.

 

9.3 Integration.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section
2 of the Securities Act) that would be integrated with the offer or sale of the Ordinary Shares and Warrants for purposes of the rules
and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction unless
shareholder approval is obtained before the closing of such subsequent transaction.

 

9.4 Securities
Laws Disclosure; Publicity; Rights Plan. The Company shall file a Current Report on Form 6-K with the Commission describing the terms
of the transaction. From and after the Form 6-K, the Company represents to the Investor that it shall have publicly disclosed all material,
non-public information delivered to the Investor by the Company or any of its Subsidiaries, or any of their respective officers, directors,
employees or agents in connection with the transactions contemplated by the Agreement. In addition, effective upon the issuance of Form
6-K, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written
or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates
on the one hand, and any Investor or any of their Affiliates on the other hand, shall terminate. The Company shall not publicly disclose
the name of the Investor, or include the name of the Investor in any filing with the Commission or any regulatory agency or Trading Market,
without the prior written consent of the Investor, except (a) as required by federal securities laws and (b) to the extent such disclosure
is required by law or Trading Market regulations, in which case the Company shall provide the Investor with prior notice of such disclosure
permitted under this clause (b). No claim will be made or enforced by the Company or, with the consent of the Company, any other Person,
that the Investor is an “Acquiring Person” under any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company,
or that the Investor could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Investor Shares
under the Agreement.

 

     6

     

    

 

9.5 Non-Public
Information. Except with respect to the material terms and conditions of the transactions contemplated by the Agreement, which shall
be disclosed pursuant to Section 9.4, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will
provide the Investor or its agents or counsel with any information that constitutes, or the Company believes constitutes, material non-public
information, unless prior thereto the Investor shall have consented to the receipt of such information, which consent shall constitute
the Investor’s agreement to keep such information confidential. The Company understands and confirms that the Investor shall be
relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company delivers any
material, non-public information to the Investor without the Investor’s consent, the Company hereby covenants and agrees that the
Investor shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors,
agents, employees or Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, agents,
employees or Affiliates not to trade on the basis of, such material, non-public information, provided that the Investor shall remain subject
to applicable law. The Company understands and confirms that the Investor shall be relying on the foregoing covenant in effecting transactions
in securities of the Company.

 

9.6 Indemnification
of Investor. Subject to the provisions of this Section 9.6, the Company will indemnify and hold the Investor and its directors, officers,
shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such
titles notwithstanding a lack of such title or any other title), each Person who controls the Investor (within the meaning of Section
15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or
employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title
or any other title) of such controlling persons (each, an “Investor Party”) harmless from any and all losses, liabilities,
obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and
reasonable attorneys’ fees and costs of investigation that any such Investor Party may suffer or incur as a result of or relating
to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in the Agreement or (b) any action
instituted against the Investor Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company
who is not an Affiliate of such Investor Parties, with respect to any of the transactions contemplated by the Agreement (unless such action
is based upon a breach of such Investor Party’s representations, warranties or covenants under the Agreement or understandings such
Investor Parties may have with any such stockholder or any violations by such Investor Parties of state or federal securities laws or
any other conduct by such Investor Parties which constitutes fraud, gross negligence, willful misconduct or malfeasance). If any action
shall be brought against any Investor Party in respect of which indemnity may be sought pursuant to this Agreement, such Investor Party
shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own
choosing reasonably acceptable to the Investor Party. Any Investor Party shall have the right to employ separate counsel in any such action
and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Investor Party except
to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed
after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion
of such separate counsel, a material conflict on any material issue between the position of the Company and the position of such Investor
Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel.
The Company will not be liable to any Investor Party under this Agreement (y) for any settlement by an Investor Party effected without
the Company’s prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the
extent that a loss, claim, damage or liability is attributable to any Investor Party’s breach of any of the representations, warranties,
covenants or agreements made by such Investor Party in this Agreement. The indemnification required by this Section 9.6 shall be made
by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills relating to indemnifiable
amounts are received by the Company. The indemnity agreements contained herein shall be in addition to any cause of action or similar
right of any Investor Party against the Company or others and any liabilities the Company may be subject to pursuant to law.

 

     7

     

    

 

9.7 Listing
of Ordinary Shares. The sale of the Ordinary Shares and Ordinary Shares underlying the Warrants by the Company to the Investor is
condition upon approval of the additional listing of the Ordinary Shares by the Trading Market. The Company hereby agrees to use best
efforts to maintain the listing or quotation of the Ordinary Shares on the Trading Market on which it is currently listed, and concurrently
with the Closing, the Company shall apply to list or quote all of the Investor Shares on such Trading Market and promptly secure the listing
of all of the Investor Shares on such Trading Market. The Company further agrees, if the Company applies to have the Ordinary Shares traded
on any other Trading Market, it will then include in such application all of the Investor Shares. The Company will then take all action
reasonably necessary to continue the listing or quotation and trading of its Ordinary Shares on a Trading Market and will comply in all
respects with the Company’s reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company
agrees to maintain the eligibility of the Ordinary Shares for electronic transfer through the Depository Trust Company or another established
clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established
clearing corporation in connection with such electronic transfer. As of the date hereof, the Company has reserved and the Company shall
continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Ordinary Shares for the
purpose of enabling the Company to issue Investor Shares pursuant to this Agreement.

 

Agreed and Accepted on August __, 2021

 

	Glory Star New Media Group Holdings Limited	 
	 	 	 	 
	 	 	 	 
	By:	Name: 	Bing Zhang	 
	 	Title:	Chief Executive Officer	 

 

[Company Signature Page to Glory Star New Media Group Holdings Limited
Subscription Agreement]

 

     8

     

    

Please confirm that the foregoing correctly sets forth the agreement
between us by signing in the space provided below for that purpose.

 

Dated: August __, 2021

 

	 	INVESTOR
	 	 
	 	 
	 	By:
	 	Title:
	 	 
	 	Address:	 
	 	 	 

 

Ordinary Shares and Warrants to be issued in the following exact name(s):

 

	Name	Mailing
    and Delivery Address 	Ordinary
    Shares

    to be DRS unless

    box checked
	 

    ________________________

     
	 

    ______________________________
	 

    ☐

 

Warrants will be delivered by certificated form in the exact name indicated
above.

 

[Investor Signature Page to Glory Star New Media
Group Holdings Limited Subscription Agreement]

 

     9

     

    

 

ANNEX I

 

TERMS AND CONDITIONS FOR PURCHASE OF ORDINARY SHARES
AND WARRANTS

 

1. Authorization
and Sale of the Ordinary Shares and Warrants. Subject to the terms and conditions of this Agreement, the Company has authorized the
sale of the Securities.

 

2. Agreement
to Sell and Purchase the Ordinary Shares and Warrants. At the Closing (as defined in Section 3.1 below), the Company will sell to
the Investor, and the Investor will purchase from the Company, upon the terms and conditions set forth herein, the Purchased Shares and
the Purchased Warrants for the Total Purchase Price.

 

3. Closing
and Delivery of the Ordinary Shares and Warrants and Purchase Price.

 

3.1 Closing.
The completion of the purchase and sale of the Ordinary Shares and Warrants (the “Closing”) of each tranche shall occur at
a place and time (the “Closing Date”) to be specified by the Company and the Investor. At the Closing of each tranche, (a)
the Company shall cause the Transfer Agent to deliver to the Investor the Purchased Shares registered in the name of the Investor pursuant
to DRS, or in the alternative, at the request of the Investor, certificates representing the Purchased Shares to the Investor; (b) the
Company shall deliver to the Investor the Warrants for the Purchased Warrants registered in the name of the Investor and (c) each tranche
payment for the Purchased Shares and Purchased Warrants of each tranche being purchased by the Investor will be delivered by or on behalf
of the Investor to the Company.

 

3.2 Conditions
to the Company’s Obligations. The Company’s obligation to issue and sell the Purchased Shares and Purchased Warrants to
the Investor shall be subject to: (i) the receipt by the Company of the Total Purchase Price, (ii) the accuracy of the representations
and warranties made by the Investor and the fulfillment of those undertakings of the Investor to be fulfilled prior to the Closing Date,
and (iii) the conditional acceptance of the Offering by the Nasdaq Stock Market.

 

4. Representations,
Warranties and Covenants of the Investor. The Investor acknowledges, represents and warrants to, and agrees with, the Company that:

 

4.1 The
Investor has full right, power, authority and capacity to enter into this Agreement and to consummate the transactions contemplated hereby
and has taken all necessary action to authorize the execution, delivery and performance of this Agreement, and this Agreement constitutes
a valid and binding obligation of the Investor enforceable against the Investor in accordance with its terms, except as enforceability
may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting
parties’ rights generally and except as enforceability may be subject to general principles of equity (regardless of whether such
enforceability is considered in a proceeding in equity or at law) and except as to the enforceability of any rights to indemnification
or contribution that may violate the public policy underlying any law, rule or regulation (including any federal or state securities law,
rule or regulation).

 

4.2 The
Investor had had a reasonable opportunity to ask questions of and receive answers from a person or persons acting on behalf of the Company
concerning the Offering and sale of the Securities and the business, financial condition and results of operations of the Company, and
all such questions have been answered to the full satisfaction of the Investor.

 

     1

     

    

 

4.3 
In evaluating the suitability of an investment in the Company, the Investor has not relied upon any representation or information (oral
or written) other than as stated in this Agreement and the Disclosure Package. In making an investment decision the Investor has solely
relied on its own examination of the Company, the Disclosure Package, the terms of the Offering, including the merits and risks involved.

 

4.4 The
Investor is able bear the financial risks of its investment. The Investor has significant prior investment experience. The Investor is
knowledgeable about investment considerations in companies like the Company. The Investor has a sufficient net worth to sustain a loss
of its entire investment in the Company in the event such a loss should occur. The Investor’s overall commitment to investments
is not excessive in view of the Investor’s net worth and financial circumstances and the purchase of the Securities will not cause
such commitment to become excessive. The investment in the Securities is a suitable one for the Investor.

 

4.5 
The Investor has taken no action that would give rise to any claim by any person for brokerage commissions, finders’ fees or the
like relating to the Agreement or the transactions contemplated hereby.

 

4.6 The
Securities to be purchased by the Investor are being acquired for the Investor’s own account, not as nominee or agent, and not with
a view to the resale or distribution of any part thereof in violation of the Act, and the Investor has no present intention of selling,
granting any participation in, or otherwise distributing the same in violation of the Act.

 

4.7 Since
the date on which the Company or its agents first contacted the Investor, its representative, about the Offering, the Investor has maintained
information about the Offering in confidence (other with respect to disclosures to the Investor’s advisors who are under a legal
obligation of confidentiality) and has not engaged in any transactions in the securities of the Company. The Investor covenants that it
has not and will not engage in any transactions in the securities of the Company or disclose any information about the Offering (other
than to its advisors who are under a legal obligation of confidentiality) prior to the time that the transactions contemplated by the
Agreements are publicly disclosed by the Company.

 

4.8 The Investor understands that nothing
in this Agreement, the Prospectus, the Disclosure Package, the Offering Information or any other materials presented to the Investor in
connection with the purchase of the Securities constitutes legal, tax or investment advice. The Investor has consulted such legal, tax
and investment advisors and made such investigation as it, in its sole discretion, has deemed necessary or appropriate in connection with
its purchase of Securities. The Investor has received all documents requested by the Investor, have carefully reviewed them and understand
the information contained therein.

 

4.9 The Investor was not induced to invest
in the Company or in the Securities by any form of general solicitation or general advertising including, but not limited to, the following:
(i) any advertisement, article, notice or other communication published in any newspaper, magazine or similar media or broadcast over
the news or radio; or (ii) any seminar or meeting whose attendees were invited by any general solicitation or advertising.

 

4.10 The Investor is not a U.S. Person
within the meaning of Rule 902(k) of Regulation S of the Securities Act of 1933, as amended.

 

     2

     

    

 

5. Survival
of Representations, Warranties and Agreements. Notwithstanding any investigation made by any party to this Agreement, all covenants,
agreements, representations and warranties made by the Investor herein will survive the execution of this Agreement, the delivery to the
Investor of the Securities being purchased and the payment therefor.

 

6. Changes.
This Agreement may not be modified or amended except pursuant to an instrument in writing signed by the Company and the Investor.

 

7. Headings.
The headings of the various sections of this Agreement have been inserted for convenience of reference only and will not be deemed to
be part of this Agreement.

 

8. Severability.
In case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity, legality and
enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby.

 

9. Governing
Law. This Agreement will be governed by, and construed in accordance with, the laws of the New York, without giving effect to the
principles of conflicts of law that would require the application of the laws of any other jurisdiction.

 

10. Counterparts.
This Agreement may be executed in two or more counterparts, each of which will constitute an original, but all of which, when taken together,
will constitute but one instrument, and will become effective when one or more counterparts have been signed by each party hereto and
delivered to the other parties. The Company and the Investor acknowledge and agree that the Company shall deliver its counterpart to the
Investor along with the Prospectus Supplement (or the filing by the Company of an electronic version thereof with the Commission).

 

11. Confirmation
of Sale. The Investor acknowledges and agrees that such Investor’s receipt of the Company’s signed counterpart to this
Agreement, together with the Prospectus Supplement (or the filing by the Company of an electronic version thereof with the Commission),
shall constitute written confirmation of the Company’s sale of shares of Securities to such Investor.

Exhibit

 

     3

     

    

 

Exhibit A

 

Notice of Purchase of Ordinary Shares and Warrants

 

Glory Star New Media Group Holdings Limited

 

Pursuant to that Subscription Agreement dated August
__, 2021 by and between Glory Star New Media Group Holdings Limited and ___________ (“Investor”), Investor has agreed to purchase
up to USD$10,000,000 in Ordinary Shares and Warrants in tranches to be completed by September 30, 2021.

 

Investor Hereby Notifies the Company of its intend to purchase the
following tranche of Ordinary Shares and Warrants as follows:

 

	Tranche Purchase Price:	USD$__________
	Combined Per Share-Warrant Price:	USD$3.50
	Number of Purchased Shares:	_______________
	Number of Warrants:	_______________
	Tranche Payment Date	_______________

 

In connection with the purchase of the Ordinary
Shares and Warrants, the Investor will pay the sum of $_________ by certified or official bank check (or via wire transfer) to the Company
by the Tranche Payment Date.

 

	Dated: _______________	 	Investor
	 	 	 
	 	 	 
	 	 	By: 

 

     1Exhibit
10.1

 

TELEMEDICINE
SERVICES AGREEMENT

 

This
Telemedicine Agreement (the “Agreement”) dated August 15, 2021 (the “Effective Date”),
is by and between ZipDoctor, Inc., a Texas corporation (“ZipDoctor”), a wholly-owned subsidiary of American
International Holdings Corp., a Nevada corporation, and Murphy RX, LLC, a Texas limited liability company, (“Murphy”),
collectively the “Parties” and each a “Party”.

 

1.
Definitions. The defined terms in the introductory paragraph, the defined terms set forth below,
and the defined terms in the remainder of this Agreement each has the meaning so given to it whenever used throughout this Agreement.

 

(a)
“Liability” means with respect to any Person, any liability or obligation of such Person of any kind, character
or description, whether known or unknown, absolute or contingent, accrued or unaccrued, disputed or undisputed, liquidated or unliquidated,
secured or unsecured, joint or several, due or to become due, vested or unvested, executory, determined, determinable or otherwise, and
whether or not the same is required to be accrued on the financial statements of such Person.

 

(b)
“Losses” means all loss, Liability, damage or deficiency (including interest, penalties, judgments, costs of
preparation and investigation, and attorneys’ fees).

 

(c)
“Members” shall mean customers of ZipDoctor’s ZipDoctor Services.

 

(d)
“Person” means any individual, corporation, partnership, joint venture, limited liability company, trust, unincorporated
organization or governmental entity.

 

(e)
“Providers” mean licensed physicians who have contracted with, and who are made available for Telemedicine
Services through ZipDoctor.

 

(f)
“Telemedicine Services” means acute virtual physician visits and optionally, mental health therapy, delivered
virtually.

 

(g)
“ZipDoctor Services” means the provision by ZipDoctor of Telemedicine Services through the ZipDoctor Website,
pursuant to and subject to the Terms and Conditions set forth on Exhibit A.

 

(h)
“ZipDoctor Website” means a website and the related platform which facilitates the provision of ZipDoctor Services.

 

2.
Scope of Agreement. The Parties are entering into this Agreement to set forth the framework pursuant to which ZipDoctor will
a) develop and provide Murphy with access to a centralized technology platform to collect and manage patient demographics, insurance
information, and acute health information for the purpose of being reviewed for recommended treatment by ZipDoctor’s network of
Providers (the “Technology Platform”), and b) provide these patients with access to ZipDoctor Services available through
the ZipDoctor Website with all Telemedicine Services being provided by ZipDoctor and its Providers; and for Murphy to pay ZipDoctor the
fees for the use of the Technology Platform and provision of such Telemedicine Services as described herein.

 

3.
Support Period. ZipDoctor agrees to provide continued support for the ZipDoctor Website during the Term of this Agreement
(the “Support Period”). The Support Period shall apply to any bugs or issues relating to the features specified
in Exhibit A and any updates required so that the ZipDoctor Website will continue to be fully-functional in all modern
internet browsers and on all mobile devices and not to create new functionality for the ZipDoctor Website. This support will be provided
to ZipDoctor at no additional cost.

 

    	Telemedicine Services Agreement
Page 1 of 8

    	 	 	 

    

 

4.
Responsibilities of ZipDoctor.

 

4.1.
Provision of Scope of Features. ZipDoctor shall provide the Scope of Agreement to Murphy throughout the Term.

 

4.2.
Sole Responsibility for All Medical and Professional Matters. All medical and medically based professional matters relating to
the “practice of medicine” shall be the sole responsibility of ZipDoctor and ZipDoctor’s Providers. ZipDoctor
expressly represents that services performed via the ZipDoctor Services shall be conducted solely by licensed and credentialed Providers
that have contracted with ZipDoctor.

 

4.3.
Providers. ZipDoctor shall retain, and compensate, all Providers who independently practice medicine. With respect to physicians,
ZipDoctor shall only contract with licensed physicians meeting applicable credentialing guidelines required by the various states in
which such physicians operate, and that meet the standards typically required of contracted extended care facilities. ZipDoctor shall
be responsible for the payment of wages, compensation, payroll taxes, employee benefits, and all other taxes and charges now or hereafter
applicable to Providers.

 

4.4.
Compliance with Law. ZipDoctor shall require in its contractual relationships with all of its Providers that they comply with
all laws, regulations, and ethical and professional standards applicable to the practice of telemedicine, including, but not limited
to state-specific telemedicine licenses. Physicians providing medical services shall at all times be licensed to practice medicine in
the states where ZipDoctor offers services, including, but not limited to the ZipDoctor Services.

 

4.5.
Availability. Providers shall be available to provide Telemedicine Services to Members in a courteous and prompt fashion, be available
and accessible to Members, provide Members with full and meaningful information, and render Telemedicine Services in a manner that assures
continuity of care.

 

4.6.
Patient Referrals. The parties agree that the benefits to Murphy hereunder do not require, are not payment for, and are not in
any way contingent upon, referral or any other arrangements for the provision of any item or service offered by ZipDoctor or any affiliate
of ZipDoctor to any Provider, designated health care service provider or facility. At all times, the Parties represent their intent to
adhere to all Federal and State laws and regulations regarding patient referrals.

 

5.
Fees, Member Charges & Billing. It is agreed that Murphy shall be responsible for the payment to ZipDoctor of the
following fees during the Term:

 

5.1.
Fees. For all services agreed to be provided hereunder and for all representations, warranties and requirements hereunder, Murphy
agrees to pay ZipDoctor the fees and amounts set forth on Exhibit B (collectively, the “Fees”).

 

5.2.
ZipDoctor shall be allowed to terminate the service to a particular Member for non-compliance with any applicable rules, regulations
or agreements regarding the use of the site or with applicable laws or regulations, or to exercise other remedies allowed at law or in
equity. ZipDoctor will notify Murphy of any such instance including the name of Member and reason for termination.

 

    	Telemedicine Services Agreement
Page 2 of 8

    	 	 	 

    

 

ZipDoctor
shall be solely responsible for paying all Providers and Murphy shall have no liability for the payment to, or actions of, any Providers.

 

6.
Assignment. Neither Party may assign any of its rights hereunder without the prior written consent of the other Party.

 

7.
Confidentiality, Non-Disclosure, and Non-Compete.

 

7.1.
Confidentiality. During the Term of this Agreement, and for a period of two years after the termination of this Agreement, except
as contemplated herein, Murphy shall not permit third parties to have access to any ZipDoctor confidential or proprietary information,
including ZipDoctor Materials, without first obtaining ZipDoctor’s written authorization and ZipDoctor shall not permit third parties
to have access to any of Murphy’s confidential or proprietary information, including Murphy Materials, without first obtaining
Murphy’s written authorization.

 

7.2.
In the event that either Party has access to, or obtains in any way, confidential and proprietary information that relates to the other
Party’s business, including, without limitation, information relating to clients and customers, sales, subscribers, subscriber
usage of websites, and all other non-public business, technical, marketing, or intellectual property information relating to each Party’s
business (“Confidential Information”), the Parties agree to preserve and protect all Confidential Information
and not disclose any Confidential Information to any third party person or entity without the prior written consent of the other Party,
both during the term of this Agreement and subsequent to the termination of this Agreement; provided however, that any Party hereto may
disclose to any other party any information already publicly known, discovered or created independent of any involvement with the other
Party or otherwise learned through legitimate means other than from such Party. Both Parties shall take such actions as may be necessary
to ensure that its employees and agents are bound by, and comply with, all the provisions of this Section. Both Parties shall be fully
responsible for all damages stemming from a breach of this duty.

 

8.
Indemnification.

 

8.1.
Indemnification by Murphy. Subject to the provisions of this Section 16, Murphy agrees to indemnify, defend and hold ZipDoctor
and its affiliates, parents, stockholders, subsidiaries, officers, directors, employees, agents, successors and assigns (such indemnified
Persons are collectively hereinafter referred to as “ZipDoctor Indemnified Persons”), harmless from and against
any and all Losses that any ZipDoctor Indemnified Person may suffer, sustain, incur or become subject to arising out of or due to: (a)
the non-fulfillment of any covenant, undertaking, agreement or other obligation of Murphy under this Agreement; (b) any inaccuracy of
any representation of Murphy in this Agreement; (c) the breach of any representation, warranty or covenant of Murphy in this Agreement;
and (d) any gross negligence or willful misconduct of Murphy or its employees. “Losses” as used in this Section
16 are not limited to matters asserted by third parties, but includes Losses incurred or sustained in the absence of third party
Claims. Payment is not a condition precedent to recovery of indemnification for Losses.

 

8.2.
Indemnification by ZipDoctor. Subject to the provisions of this Section 16, ZipDoctor agrees to indemnify, defend and hold
Murphy and its affiliates, parents, stockholders, subsidiaries, officers, directors, members, managers, employees, agents, successors
and assigns (such indemnified Persons are collectively hereinafter referred to as “Murphy Indemnified Persons”
and together with the ZipDoctor Indemnified Persons, the “Indemnified Persons”), harmless from and against
any and all Losses that any Murphy Indemnified Person may suffer, sustain, incur or become subject to arising out of or due to: (a) the
non-fulfillment of any covenant, undertaking, agreement or other obligation of ZipDoctor under this Agreement; (b) any inaccuracy of
any representation of ZipDoctor in this Agreement; (c) the breach of any representation, warranty or covenant of ZipDoctor in this Agreement;
and (d) any gross negligence or willful misconduct of ZipDoctor or its employees.

 

    	Telemedicine Services Agreement
Page 3 of 8

    	 	 	 

    

 

8.3.
In claiming any indemnification hereunder, the Party claiming indemnification (the “Claimant”) shall: (1) provide
the other Party (the “Indemnifying Party”) with prompt written notice of any claim that the Claimant believes
calls for indemnification under this Agreement; (2) grant the Indemnifying Party sole control of the defense and all related settlement
negotiations, provided that no settlement will be entered into which requires any payment or expenditure by the Claimant of any amount
without the Claimant’s consent, and (3) provide the Indemnifying Party with the assistance, information and authority necessary
to perform the above. The Claimant may, at its option and expense, be represented by separate counsel in any such action.

 

9.
Compliance with Laws. Murphy shall comply with all applicable laws, legislation, rules, regulations, and governmental requirements
with respect to ZipDoctor Services and the License, including, but not limited to, import and export restrictions, obtaining any necessary
consents and licenses, and registering or filing any documents. Murphy shall defend, indemnify, and hold ZipDoctor harmless from and
against any and all claims, judgments, costs, awards, expenses (including reasonable attorney fees), and liability of any kind arising
out of the noncompliance with applicable governmental regulations, statutes, decrees or other obligations with respect to the ZipDoctor
Services.

 

10.
Term of Agreement and Termination. The term of this Agreement shall be for one (1) year beginning on the Effective Date. Thereafter,
this Agreement shall be automatically renewed for successive one-year terms, unless either Party gives the other Party written notice
of termination at least 90 days prior to the end of the then current term (such initial term and all renewal terms, the “Term”).
Such Term is subject to prior termination as provided below.

 

10.1.
Breach. The Parties agree that any breach of one or more provisions of this Agreement (including, but not limited to any breach
of the requirements of Murphy set forth in the Exhibits hereto and/or any failure of Murphy to timely pay any amount due hereunder) that
threatens to, or causes the other Party substantial harm is a material breach. Furthermore, any breach of the confidentiality, non-disclosure,
or non-competition provisions of Section ‎7 by either Party, or failure to make payments as outlined in Section ‎5,
shall be considered material breaches. Furthermore, any conduct or negligence that adversely affects the business or good name of the
other Party will be considered a material breach, unless the offending Party immediately ceases such activity and cures any damage resulting
from such conduct or negligence within 30 days of written notice from the damaged Party.

 

10.2.
Early Termination for Cause. In the event of an actual or perceived material breach of this Agreement by either Party, the termination
provisions of this section will not trigger or be available to the non-breaching Party until the non-breaching Party has notified the
breaching Party in writing of the alleged material breach, citing in reasonable detail the nature of the breach. If the offending Party
agrees that they materially breached one or more provisions of this Agreement, then the offending Party shall then have thirty days to
remedy such breach. If at the end of such thirty-day period, the breach has not been remedied, the Agreement may be terminated by the
non-offending Party. However, if the Party accused of the material breach denies the breach in writing, or denies that it was material,
and produces reasonable evidence to support the denial, then the offending Party may not terminate the Agreement, but must utilize the
dispute resolution provisions in Section 17 hereof.

 

    	Telemedicine Services Agreement
Page 4 of 8

    	 	 	 

    

 

10.3.
Termination for Bankruptcy. Subject to applicable law, this Agreement may be terminated by either Party upon written notice (i)
upon the other Party’s making an assignment for the benefit of creditors, or (ii) upon the other Party’s dissolution or ceasing
to do business.

 

10.4.
Termination Upon Mutual Consent. This Agreement may also be terminated at any time upon the mutual written consent of both Parties.

 

10.5.
Duties Upon Termination. Upon termination of this Agreement, the following shall apply: Each Party shall return or destroy all
originals and copies of any Confidential Information of the other Party regarding this project.

 

10.6.
Force Majeure. A Party shall be excused from delays or failure to perform its duties (other than payment obligations) to the extent
such delays or failures result from acts of nature, riots, war, acts of public enemies, fires, epidemics, or any other causes beyond
its reasonable control. The Parties will promptly inform and consult with each other as to any of the above causes that in their judgment
may or could be the cause of a substantial delay in the performance of this Agreement. Either Party may, in its discretion, terminate
this Agreement if a delay in performance by the other Party exceeds or is reasonably expected to exceed six months.

 

10.7.
Waiver. The waiver by either Party of any default, breach or obligation hereunder shall be ineffective unless in writing, and
shall not constitute a waiver of any subsequent breach or default. No failure to exercise any right or power under this Agreement or
to insist on strict compliance by the other Party shall constitute a waiver of the right in the future to exercise such right or power
or to insist on strict compliance.

 

11.
Limitation of Warranties, Liabilities & Risks.

 

11.1.
LIMITATION OF WARRANTIES. ZIPDOCTOR MAKES NO WARRANTY, REPRESENTATION OR PROMISE NOT EXPRESSLY SET FORTH IN THIS AGREEMENT. ZIPDOCTOR
DISCLAIMS AND EXCLUDES ANY AND ALL IMPLIED WARRANTIES, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS
FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT.

 

11.2.
LIMITATION ON LIABILITY. BOTH PARTIES AGGREGATE LIABILITY ARISING FROM OR RELATING TO THIS AGREEMENT (REGARDLESS OF THE FORM OF
ACTION OR CLAIM - E.G. CONTRACT, WARRANTY, TORT, AND/OR OTHERWISE) WILL IN NO EVENT EXCEED AN AMOUNT EQUAL TO THE TOTAL OF THE FEES RECEIVED
BY MURPHY FROM ZIPDOCTOR UNDER THIS AGREEMENT FOR THE PRIOR TWELVE (12) MONTHS. NEITHER PARTY WILL BE LIABLE FOR ANY SPECIAL, INCIDENTAL,
CONSEQUENTIAL, INDIRECT OR PUNITIVE DAMAGES EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

 

11.3.
Allocation of Risk. This Agreement defines a mutually agreed-upon allocation of risk and the amounts payable to Murphy reflect
such allocation of risk.

 

12.
Disputes.

 

12.1.
Arbitration. Any and all disputes, controversies, claims and differences arising out of, or relating to this Agreement, or any
breach thereof, which cannot be settled through correspondence and mutual consultation of the Parties, shall be finally settled by arbitration
in accordance with the Commercial Arbitration Rules of the American Arbitration Association, in effect on the date of this Agreement,
by the arbitrators selected in accordance with this Agreement.

 

    	Telemedicine Services Agreement
Page 5 of 8

    	 	 	 

    

 

12.2.
Selection of Arbitrators. One arbitrator shall be appointed by the American Arbitration Association.

 

12.3.
Location. Arbitration proceedings shall be held in Dallas, Texas, unless the parties mutually agree to a different location. The
arbitrators shall allow the Parties sufficient time to conduct discovery. Discovery shall be in accordance with the Federal Rules of
Evidence and discovery disputes shall be resolved by the arbitrators. The date(s) of the arbitration proceeding shall be mutually agreed
upon by the Parties, but if no agreement can be had, then by the arbitrators. The decision of the arbitrator(s) on all discovery and
issues before them shall be final and binding on the Parties, not subject to appeal, and shall deal with the questions of costs of the
arbitration and all matters related thereto. Judgment upon the award or decision rendered by the arbitrator(s) may be entered in any
court having jurisdiction thereof, or application may be made to such court for a judicial recognition of the award/decision and order
of enforcement thereof, as the case may be.

 

12.4.
Governing Law. This Agreement shall be subject to the laws of the state of Texas.

 

13.
Mutual Representations, Covenants, and Warranties. Each of the Parties, for themselves and for the benefit of each of the
other Parties to this Agreement, represents, covenants, and warrants that:

 

13.1.
Each Party has all requisite power and authority, corporate or otherwise, to execute and deliver this Agreement and to consummate the
transactions contemplated by this Agreement. This Agreement constitutes the legal, valid, and binding obligation of each Party enforceable
against each other Party in accordance with its terms, except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium, or similar laws affecting creditors’ rights generally and general equitable principles;

 

13.2.
The execution and delivery by each Party and the consummation of the transactions contemplated by this Agreement do not and shall not,
by the lapse of time, the giving of notice, or otherwise: (i) constitute a violation of any law; or (ii) constitute a breach of any provision
contained in, or a default under, any governmental approval, or any writ, injunction, order, judgment, or decree of any governmental
authority, or any agreement, contract, or understanding to which the party or its assets are bound or affected; and

 

13.3.
Any individual executing this Agreement on behalf of an entity has authority to act on behalf of the entity and has been duly and properly
authorized to sign this Agreement on behalf of the entity.

 

14.
Remedies. Each Party shall be entitled to all remedies at law or in equity in enforcing a default or breach under this Agreement.
The prevailing Party in any action under this Agreement shall be entitled to recover its costs, including reasonable attorneys’
fees, incurred in enforcing this Agreement. Each Party acknowledges that any breach by the other of any of the provisions contained in
this Agreement, and more particularly a breach, or threatened breach, of the confidentiality and non-compete provisions, will give rise
to irreparable injury to such non-breaching Party inadequately compensable in monetary damages alone. Accordingly, each Party stipulates
and agrees that any Party may seek and obtain preliminary and permanent injunctive relief against the breach, or threatened breach, of
said provisions without the necessity of posting bond. Such relief will be in addition to any other legal or equitable remedies which
may be available to such Party.

 

    	Telemedicine Services Agreement
Page 6 of 8

    	 	 	 

    

 

15.
Notices. All notices, approvals, consents, requests, and other communications hereunder shall be in writing and shall be delivered
(i) by personal delivery, or (ii) by national overnight courier service, or (iii) by certified or registered mail, return receipt requested,
or (iv) via facsimile transmission, with confirmed receipt, or (v) via email. Notice shall be effective upon receipt except for notice
via fax (as discussed above) or email, which shall be effective only when the recipient, by return or reply email or notice delivered
by other method provided for in this Section ‎15, acknowledges having received that email (with an automatic “read
receipt” or similar notice not constituting an acknowledgement of an email receipt for purposes of this Section ‎15,
but which acknowledgement of acceptance shall also include cases where recipient ‘replies’ to such prior email, including
the body of the prior email in such ‘reply’). Such notices shall be sent to the applicable party or parties at the address
specified on the signature page hereof, subject to notice of changes thereof from any party with at least ten (10) business days’
notice to the other parties. Rejection or other refusal to accept or the inability to deliver because of changed address of which no
notice was given shall be deemed to be receipt of the notice as of the date of such rejection, refusal or inability to deliver.

 

16.
Publicity. ZipDoctor shall have the sole right to publicly disclose this Agreement and the terms hereof. No public disclosure
hereof shall be made by Murphy without the prior written consent of ZipDoctor.

 

17.
Independent Contractor. The Parties to this Agreement are independent contractors and there is no relationship of agency,
partnership, joint venture, employment or franchise between the Parties. Neither Party has the authority to bind the other, or to incur
any obligation on the other’s behalf.

 

18.
Headings. The section headings contained in the Agreement are for reference purposes only and shall not in any way affect
the meaning or interpretation of this Agreement.

 

19.
Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule
of law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so
long as the economic or legal substance of this Agreement is not affected in any manner adverse to any party. Upon such determination
that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith
to modify this Agreement so as to affect the original intent of the parties as closely as possible in a mutually acceptable manner.

 

20.
Entire Agreement. This Agreement and the schedules and exhibits set forth hereto, which are integral parts of this Agreement,
set forth the entire agreement between the Parties on this subject and supersedes all prior negotiations, understandings and agreements
between the Parties concerning the subject matter. No amendment or modification of this Agreement shall be made unless agreed to in writing
and signed by both Parties.

 

21.
Joint Representations. Each of the Parties represents to the other that, that (a) before executing this Agreement, said Party
has fully informed itself of the terms, contents, conditions and effects of this Agreement; (b) said Party has relied solely and completely
upon its own judgment in executing this Agreement; (c) said Party has had the opportunity to seek and has obtained the advice of its
own legal, tax and business advisors before executing this Agreement; (d) said Party has acted voluntarily and of its own free will in
executing this Agreement; and (e) this Agreement is the result of arm’s length negotiations conducted by and among the Parties
and their respective counsel.

 

22.
Signatures and Counterparts. This Agreement and any signed agreement or instrument entered into in connection with this Agreement,
and any amendments hereto or thereto, may be executed in one or more counterparts, all of which shall constitute one and the same instrument.
Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .jpeg or similar attachment to
electronic mail (any such delivery, an “Electronic Delivery”) shall be treated in all manner and respects as
an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version
thereof delivered in person. At the request of any Party, each other Party shall re execute the original form of this Agreement and deliver
such form to all other Parties. No Party shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature
or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a
contract, and each such Party forever waives any such defense, except to the extent such defense relates to lack of authenticity.

 

    	Telemedicine Services Agreement
Page 7 of 8

    	 	 	 

    

 

IN
WITNESS WHEREOF, the undersigned have executed this Agreement on the date first written above.

 

“ZipDoctor”

 

	 	ZipDoctor,
    Inc. 	 
	 	 	 
	 	 	 
	 	Jacob
    Cohen	 
	 	Chief
    Executive Officer	 
	 	 	 
	 	Address
    for Notice:	 

 

7950
Legacy Drive, Suite 400

Plano,
TX 75024

Attn:
Jacob Cohen

Email:
Jacob@amihcorp.com

 

“Murphy”

	 	 	 
	 	Murphy
    RX, LLC	 
	 	 	 
	 	 	 
	 	Austin
    Howard	 
	 	Member	 
	 	 	 
	 	Address
    for Notice:	 

 

709
Business Way

Wylie,
TX 75098

Attn:
Austin Howard

Email:
Admin@Murphy-RX.com

 

  

    	Telemedicine Services Agreement
Page 8 of 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]